Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE study
2024-516642-19-01Phase 4Completed
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of urapidil, labetalol and tranexamic acid in ischemic stroke (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Modified Rankin Scale at 90 days. Started Nov 2024; status: completed.
02
Drugs
urapidillabetaloltranexamic acid
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-516642-19-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516642-19-01.